Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.
The use of anti-tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn's disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell-mediated immunity, the most frequent being tuberculosis. We report the first case of pulmonary actinomycosis in a patient receiving regular infusions of infliximab, an anti-TNF agent, for Crohn's disease.
Cohen
R D
RD
Department of Medicine, University of British Columbia, Vancouver, Canada. richardcohen@shaw.ca
Bowie
W R
WR
Enns
R
R
Flint
J
J
Fitzgerald
J M
JM
D000196:Actinomycosis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab